Comparison of a Single Versus Double Perclose Technique for TAVR

Recruiting N/A Interventional Study
Severe Aortic Stenosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
65 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
876 (estimated)
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Transcatheter aortic valve replacement (TAVR) has become widely recognized as a minimally invasive approach for aortic valve replacement in patients with severe aortic stenosis. It has been proven to be a safe and effective option for patients who are at low, intermediate, and prohibitive risk for surgical valve replacement. One of the critical components of procedural success in a transfemoral a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients scheduled to undergo transfemoral TAVR were considered for inclusion in the trial if they met all inclusion and none of the exclusion criteria. Inclusion criteria were an indication for TAVR as judged by the local heart team; selection of the transfemoral access route…
Contacts

XianBao Liu, PhD

13857173887

liuxb@zju.edu.cn

CONTACT